We are live on ! Find out more
APLS

Apellis Pharmaceuticals
APLS

Delisted

APLS was delisted on the 13th of May, 2026.

Back to rankings

255 hedge funds and large institutions have $2.8B invested in Apellis Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 49 funds opening new positions, 91 increasing their positions, 76 reducing their positions, and 52 closing their positions.

New
Increased
Maintained
Reduced
Closed

34% more call options, than puts

Call options by funds: $26.6M | Put options by funds: $19.8M

20% more repeat investments, than reductions

Existing positions increased: 91 | Existing positions reduced: 76

0.1% more ownership

Funds ownership: 101.87% → 101.97% (+0.1%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

6% less first-time investments, than exits

New positions opened: 49 | Existing positions closed: 52

2% less funds holding

Funds holding: 260 → 255 (-5)

31% less capital invested

Capital invested by funds: $4.04B → $2.8B (-$1.24B)

Holders
255
Holders Change
-5
Holders Change %
-1.92%
% of All Funds
3.42%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
49
Increased
91
Reduced
76
Closed
52
Calls
$26.6M
Puts
$19.8M
Net Calls
+$6.76M
Net Calls Change
-$64.2M

Top Buyers

Rank Fund Capital Flow
1
AQR Capital Management
AQR Capital Management
Connecticut
+$61.4M
2
Bank of America
Bank of America
North Carolina
+$40.1M
3
O
OrbiMed
New York
+$39.6M
4
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board
Ontario, Canada
+$28M
5
Man Group
Man Group
United Kingdom
+$27M

Top Sellers

Rank Fund Capital Flow
1
CWM
CIBC World Markets
New York
-$41M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$40.5M
3
OCA
Octagon Capital Advisors
New York
-$25.2M
4
Toronto Dominion Bank
Toronto Dominion Bank
Ontario, Canada
-$23.1M
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$20M
Name Holding Trade Value Shares
Change 		Change in
Stake
WA
251
WPG Advisers
Maryland
$109 – – –
CFD
252
Creative Financial Designs
Indiana
$109 +$138 +5 New
MCM
253
Manchester Capital Management
Vermont
$66 – – –
CWM
254
CIBC World Markets
New York
– -$41M -1,285,300 Closed
Point72 Asset Management
255
Point72 Asset Management
Connecticut
– -$40.5M -1,267,958 Closed
LGM
256
Logos Global Management
California
– -$16M -500,000 Closed
IHAM
257
Integral Health Asset Management
New York
– -$13.4M -420,000 Closed
MSE
258
MUFG Securities EMEA
United Kingdom
– -$9.51M -298,000 Closed
Renaissance Technologies
259
Renaissance Technologies
New York
– -$8.68M -271,913 Closed
IECM
260
Intrinsic Edge Capital Management
Illinois
– -$6.38M -200,000 Closed
PE
261
Point72 Europe
United Kingdom
– -$6.15M -192,694 Closed
CSS
262
Cubist Systematic Strategies
Connecticut
– -$6.12M -191,687 Closed
Capital Fund Management (CFM)
263
Capital Fund Management (CFM)
France
– -$3.87M -121,433 Closed
EAM
264
Exome Asset Management
New York
– -$3.81M -119,467 Closed
BPC
265
Banque Pictet & Cie
Switzerland
– -$3.1M -97,299 Closed
CCM
266
Cinctive Capital Management
New York
– -$2.78M -86,991 Closed
FCM
267
Fieldview Capital Management
Michigan
– -$1.96M -61,405 Closed
AAA
268
Affinity Asset Advisors
New York
– -$1.6M -50,000 Closed
TD Asset Management
269
TD Asset Management
Ontario, Canada
– -$1.23M -38,692 Closed
RAM
270
Readystate Asset Management
Illinois
– -$1.13M -35,561 Closed
SC
271
Savant Capital
Illinois
– -$1.01M -31,525 Closed
PCM
272
Prelude Capital Management
New York
– -$997K -31,255 Closed
SCA
273
Sippican Capital Advisors
Massachusetts
– -$662K -20,753 Closed
D.E. Shaw & Co
274
D.E. Shaw & Co
New York
– -$553K -20,000 Closed
SC
275
Syon Capital
California
– -$621K -19,455 Closed
9 10
11
12 13

APLS Hedge Fund Activity: Q1 2025 in Review

255 of the 7,464 institutional investors tracked by Wall St. Rank reported a position in Apellis Pharmaceuticals (APLS) for Q1 2025, worth a combined $2.8B — down 31% from $4.04B a quarter earlier.

Sellers outnumbered buyers: 52 funds closed out of APLS and 49 opened new positions — a net loss of 3 holders — while 76 trimmed existing stakes and 91 added.

The largest buyer was AQR Capital Management, adding an estimated $61.4M. The largest seller was CIBC World Markets, exiting entirely with an estimated $41M sold.

  • 255 institutional investors held Apellis Pharmaceuticals (APLS) as of Q1 2025, down from 260 in Q4 2024.
  • Funds reported $2.8B of Apellis Pharmaceuticals stock for Q1 2025, down 31% quarter-over-quarter.
  • 49 funds opened new Apellis Pharmaceuticals positions in Q1 2025 and 52 closed out, a net change of -3 holders.
  • The largest Apellis Pharmaceuticals buyer in Q1 2025 was AQR Capital Management, an estimated $61.4M added.
  • The largest Apellis Pharmaceuticals seller in Q1 2025 was CIBC World Markets, an estimated $41M sold.

Based on aggregated 13F filings for Q1 2025.